Exelixis | EXEL - Efectivo Y Equivalentes





Efectivo Y Equivalentes Cambio Fecha
Acadia Pharmaceuticals USD 851.46M 31.77M 2026-03
Agios Pharmaceuticals USD 113.6M 24.47M 2026-03
Akebia Therapeutics USD 162.64M 22.2M 2026-03
Amgen USD 12.04B 2.91B 2026-03
AstraZeneca USD 7.56B 1.85B 2026-03
Bayer EUR 6.67B 774M 2025-12
BioMarin Pharmaceutical USD 2.22B 910.76M 2026-03
Bristol-Myers Squibb USD 9.57B 635M 2026-03
Cytokinetics USD 129.84M 7.32M 2026-03
Eisai JPY 301.65B 16.27B 2025-09
Eli Lilly USD 5.28B 1.99B 2026-03
Exelixis USD 226.15M 256.34M 2026-03
Genmab DKK 1.72B 46M 2025-12
Glaxosmithkline GBP 3.44B 146M 2026-03
Incyte USD 4.02B 435.22M 2026-03
Ionis Pharmaceuticals USD 1.92B 758M 2026-03
MacroGenics USD 66.52M 9.3M 2026-03
Merck USD 5.33B 9.24B 2026-03
Moderna USD 1.91B 687M 2026-03
Nektar Therapeutics USD 15.12M 25.92M 2025-12
Neurocrine Biosciences USD 266.5M 446.5M 2026-03
Novartis USD 7.62B 739M 2026-06
Pfizer USD 1.7B 561M 2026-03
Puma Biotechnology USD 53.52M 1.14M 2025-09
Sanofi EUR 5.54B 2.11B 2026-03
Takeda JPY 654.94B 26.55B 2025-12
Ultragenyx Pharmaceutical USD 175M 246M 2026-03
Xencor USD 14.17M 39.9M 2026-03